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ALLOGRAFTING IN PATIENTS WITH SEVERE, REFRACTORY APLASTIC
ANEMIA USING PERIPHERAL BLOOD STEM CELLS AND A FLUDARA-
BINE-BASED CONDITIONING REGIMEN: THE MEXICAN EXPERIENCE
Gomez-Almaguer, D.1; Vela-Ojeda, J.2; Jaime-Perez, J.C.1; Gutier-
rez-Aguirre, C.H.1; Cantu-Rodriguez, O.G.1; Sobrevilla-Calvo, P.3;
Rivas-Vera, S.3; Gomez-Rangel, J.D.4; Ruiz-Arguelles, G.J.4 1. Hos-
pital Universitario, Monterrey, Nuevo Leon, Mexico; 2. Centro Medico
la Raza, Mexico City, Mexico; 3. Instituto Nacional de Cancerologia,
Mexico City, Mexico; 4. Centro de Hematologia y Medicina Interna,
Puebla, Mexico.
We studied the effectiveness of a ﬂudarabine/cyclophosphamide-
based conditioning regimen without anti-thymocyte globulin in 23
aplastic anemia patients, who had no response to previous conven-
tional pharmacologic treatment. Patients received oral busulphan 4
mg/kg/day/2 days, IV cyclophosphamide 350 mg/m2/day/3 days
and ﬂudarabine 30 mg/m2/day/3 days. For GVHD prophylaxis
patients received MTX 5 mg/m2 days 1, 3, 6, and 11 and oral
cyclosporin-A (CyA) 5 mg/kg/day, starting on day 1. Peripheral
blood stem cell products were used with a median dose of 5.5 106
CD34/kg. The patients were followed for an average of 25
months. By a median of day 11 an ANC 0.5  109/L was
reached; and by day, 12 the platelet count had reached
20,000  109/L. Acute grade I-II GVHD occurred in 4 patients,
whereas limited chronic GVHD presented in 6 cases. Twenty one
patients (91.3%) achieved engraftment. Two patients failed to
engraft and 4 developed late rejection, two of these individuals
died, 2 survive with high transfusion requirements, whereas 2
received a second peripheral blood stem cell infusion and achieved
sustained engraftment. Currently 21 (91%) of the 23 patients are
alive, whereas 19 of 21 (90%) remain in complete remission. The
average cost was about ﬁfteen thousand US dollars for this kind of
non-myeloablative transplant. Non-myeloablative stem cell trans-
plantation represents an affordable alternative to traditional more
cytotoxic conditioning for severe aplastic anemia (SAA) patients.
Long-term effects however, remain to be evaluated.
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ONE YEAR FOLLOW UP OF 71 LEUKEMIC PATIENTS WHO RECEIVED
FLUDARABINE AND BUSULFAN (FLUBUP) AS MYELOABLATIVE CONDI-
TIONING REGIMEN FOR ALLOGENEIC PBSCT
Iravani, M.; Tavakoli, M.; Shamshiri, A.R.; Mousavi, A.; Bahar, B.;
Ghavamzadeh, A. Hematology-Oncology and BMT research Center,
Tehran University of Medical Science, Tehran, Islamic Republic of Iran.
We are evaluating ﬂudarabine (40 mg/m2 on days 6 to 2) and
busulfan (4 mg/kg/day on days 5 to 2) as a new conditioning
regimen for allogeneic peripheral blood stem cell transplantation
in leukemic patients with matched related donors. Seventy one
patients were enrolled, 18 with high and 53 with standard risk (18
ALL, 35 AML, 16 CML and 2 MDS; F29 M42). The median
patient age was 23.7 years (range, 2.4–46.7). Cyclosporine was
used as a prophylactic agent for GVHD (3 mg/kg IV till 4, 10
mg/kg oral from day 5). The median follow-up was one year
(range, 50–592 days). 91.5% and 15.5% developed mucositis and
hepatic toxicity respectively which resolved with conservative ther-
apy. There was no cardiac toxicity (except one patient with mild
pericardial effusion and another with tachycardia). The median of
highest serum creatinine level during hospitalization were 1.6
mg/dl (range, 0.8–3.7; 24.3% with Cr 2) and serum cyclosporine
level, at the same time, was 246 ng/ml (range, 9–814). 7% expe-
rienced hemorrhagic cystitis (infection was ruled out) and 36.6%
experienced moderate to severe headache. 38% and 14.1% of the
patients showed grade 1, 2 and grade 3 acute GVHD respectively.
Grade 4 acute GVHD was found in one patient. 50% and 7%
showed limited and extensive chronic GVHD. 27% of patients
became CMV (min 17, max 69). The median times for neu-
trophil and platelet recovery were 10 (min 0, max26) and 12 (min
0, max 30) days. In day 38, 86.7% of the patients had 90% or
more, mononuclear chimerism (with STR-PCR technique; me-
dian, 97%; range, 25–100). 5 ALL and 8 AML patients relapsed
(18.3% of all patients, post transplantation lymphoproliferative
disease was found in one of them) and 8 (11%) died after relapse.
Nonrelapse mortality was 15.5% (11 patients; acute GVHD grade
IV1, CMV infection and GVHD2, CMV infection2, pneu-
monia2, infection2, chronic GVHD2). With a median follow
up of one year (range, 1.6–20 months), the probability of overall
survival and disease free survival was 73% and 66% respectively. It
could be beneﬁcial to use ﬂudarabine versus cyclophosphamide in
standard conditioning regimen for leukemic patients because of
reduced toxicity, low incidence of acute GVHD and facilitated
donor engraftment.
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ALLOGENEIC BONE MARROW TRANSPLANTATION IN -THALAS-
SAEMIA—SINGLE CENTER STUDY
Hashmi, K.U.; Raza, S.; Khattak, B.K.; Ahmed, P.; Hussain, I. Armed
Forces Bone Marrow Transplant Center, Rawalpindi, Punjab, Pakistan.
Objective: To evaluate outcome of allogeneic BMT in -thalas-
saemia at Armed Forces Bone Marrow Transplant Center, Paki-
stan. Methods: Twenty-ﬁve patients with -thalassaemia under-
went allogeneic BMT/PBSC transplantation from HLA identical
sibling donors. Patients were classiﬁed in three groups according to
Pesaro (Italy) risk classiﬁcation. Class-I (n12) and Class-II (n8)
patients received conditioning with Bu14/Cy200, whereas Class-
III (n5) patients received conditioning with hydroxyurea, aza-
thioprine, ﬂudarabine, along with Bu14/Cy200. Cyclosporine,
prednisolone and methotrexate were given for GvHD prophylaxis.
Stem cells dose infused was 4.0  108/kg body weight of the
patient. Results: Since August 2001 till September 2004 a total of
25 patients suffering from -thalassaemia major underwent allo-
geneic bone marrow transplantation. Out of these 20 were males
and 5 females (male:female ratio 4:1). Ages ranged between 9
months to 14 years (median age: 4.64 years). Twelve patients were
in risk class-I, whereas 8 patients in class-II and 5 patients were in
risk class-III. Engraftment was seen in all the patients. Median time
to neutrophil recovery (ANC 0.5  109/l) was 13 days and
platelet recovery (20  109/l) was 15 days. Secondary graft
rejection was observed in 5 patients (20%) between 2–4 months
post transplant. Three patients were subjected to 2nd transplant,
out of these 2 achieved successful engraftment whereas 1 again
reverted back to -thalassaemia, whereas 1 died of VOD liver.
Acute GvHD was observed in 15 patients (60%). Grade-I acute
GvHD was seen in 09 patients (36%), Grade-II GvHD in 2
patients (8%), grade-III GvHD in 3 patients (12%) and grade-IV
GvHD in 1 patient (4%). Other common non infective complica-
tions were hypertension (n5) 20%, ﬁts (n3) 12%, VOD liver
(n2) 8%, haemorrhagic cyctic (n2) 8%. Major post transplant
infective complications were disseminated CMV infection (n2)
8%, pseudomonas septicemia (n1) 4%, disseminated tuberculosis
(n1) 4%. Overall mortality in all risk classes was 28% (n7).
Overall survival was (n18) 72%. Class wise survival was (10/12)
83.33% in Class-I, class-II (5/8) 62.5% and in Class-III (3/5) 60%.
Conclusion: Allogeneic BMT is the only curative therapy for
-thalassaemia patients, however the success rate can be increased if
the patients are selected carefully and transplanted at an early age.
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FACILITATING CELL (FC)-MEDIATED ALLOENGRAFTMENT OCCURS IN
THE CONTEXT OF IN VIVO REGULATORY T-CELL INDUCTION
Shinde Patil, V.R.; Colson, Y.L. Brigham and Women’s Hospital &
Harvard Medical School, Boston, MA.
21B B & M T
Engraftment failure and graft-versus-host disease (GVHD) serve
as major impediments to successful clinical bone marrow trans-
plantation (BMT). We have previously shown in a murine model
that supplementing puriﬁed allogeneic hematopoietic stem cells
(SC) with a population of CD8dTCR bone marrow-de-
rived cells results in markedly enhanced engraftment and complete
donor chimerism across full MHC barriers. Unlike T cells, these
facilitating cells (FC) do not result in GVHD even in semi-allo-
geneic parent3F1 aggressive GVHD models. Recent reports have
suggested that GVHD can be suppressed by the administration of
ex-vivo expanded CD4CD25 regulatory T cells. Although the
FC is not a T cell, we hypothesized that FC-mediated tolerance
may result from a similar mechanism. In order to investigate the
unmitigated GVHD effector activity of the FC, puriﬁed donor SC
and FC inocula were transplanted within a semi-allogeneic, hap-
loidentical model of lethal GVHD. Unlike T-cell recipients that
succumbed to lethal GVHD, all FC-recipients were free from any
evidence of GVHD. Analysis of the recipient splenocytes revealed
a signiﬁcant up-regulation of regulatory T-cell genes CTLA4,
GITR and FoxP3, suggesting that the inhibition of GVHD in a
semi-allogeneic model was coupled to an in vivo induction of
regulatory T-cells. To further delineate this FC-coupled effect in
a fully allogeneic murine BMT model, lethally irradiated B10.BR
recipients were transplanted with SCFC derived from C57BL/6
(B6) murine bone marrow (BM), while lethally irradiated B6 re-
cipients transplanted with B6-derived SC alone served as radiation
controls since SC alone or SCTBM(BM derived T-cells) fail to
engraft in fully allogeneic recipients when the FC is absent. The
fully allogeneic SCFC recipients displayed excellent engraftment
and complete donor chimerism without GVHD. Surprisingly, a
signiﬁcant number of CD4CD25regulatory T-cells (2.3 	
0.23%) were detected by ﬂow cytometric analysis of splenocytes
harvested from these SCFC allogeneic recipients. Of even
greater interest, was the marked increase of this regulatory T-cell
subset (2.2 	 0.9%) in the BM of FC recipients compared with
negligible regulatory cell presence in the BM of syngeneic B6
control recipients (0.27%). For the ﬁrst time, our studies indicate
that FC-mediated alloengraftment and lack of GVHD in a fully
allogeneic murine model occurs in association with the induction
of regulatory T-cells in vivo.
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THE RESULTS OF RISK ADAPTED PRE-EMPTIVE THERAPY OF CMV
INFECTION WITH GANCICLOVIR IN 169 PATIENTS, AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HEMATOLOGY-
ONCOLOGY AND BMT RESEARCH CENTER
Iravani, M.; Faghih, A.H.; Shamshiri, A.R.; Toutounchi, M.; Tavakoli,
M.; Mousavi, A.; Bahar, B.; Alimoghadam, K.; Jahani, M.; Gha-
vamzadeh, A. Hematology-Oncology and BMT Research Center, Tehran
University of Medical Science, Tehran, Islamic Republic of Iran.
During an 18 month period, we studied on 169 allogeneic HSCT
in Hematology- Oncology and BMT Research Center, Tehran
University of Medical Sciences. Patients were evaluated for PP.65
CMV antigen by immuno ﬂuorescence method every 10–14 days
during ﬁrst 100 post-transplant days. 74 patients had positive test
for at least one time. We treated 41 asymptomatic patients by
risk-adapted pre-emptive therapy strategy with ganciclovir. Higher
age at the time of transplant, non sibling and HLA mismatch
transplant, disease for which transplant was done (AML and CML
vs. ALL and thalassemia), grade of acute GVHD, higher maximum
cyclosporine level, systemic steroid consumption, and pre-trans-
plant immunosuppressive regimen (MTX and cyclosporine vs. cy-
closporine alone) all had association with antigenemia. Event free
survival in 100 and 180 post transplant days were 90% and 84%,
respectively. There was no signiﬁcant difference between ﬁrst 100
post transplant days mortality of patients with and without anti-
genemia, and patients with and without pre-emptive ganciclovir
treatments. Mortality in30180 post-transplant days of patients
with ganciclovir treatment was higher than without treatment
group. Ganciclovir effectively omitted antigenemia in 98% of pa-
tients. In 64% of patients, there was not antigenemia relapse after
pre-emptive therapy. Asymptomatic antigenemia relapse and
symptomatic antigenemia relapse occurred in 28% and 8% of
patients respectively. 57% of relapses were early and 43% were
late. Leukopenia was the major side effect of ganciclovir therapy.
47% of patients used at least one dose of GCSF. Pre-treatment
leukocyte count predicted post-treatment leukocyte count in pa-
tients.
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MYELOABLATIVE CONDITIONING WITH FLUDARABINE AND BUSULFAN
FOR ALLOGENEIC PBSCT IN CHRONIC PHASE CML
Iravani, M.; Tavakoli, M.; Shamshiri, A.R.; Mousavi, A.; Bahar, B.;
Jahani, M.; Ghavamzadeh, A. Hematology-Oncology and BMT Re-
search Center, Tehran University of Medical Science, Tehran, Islamic
Republic of Iran.
We have studied a regimen comprising intravenous ﬂudarabine
(40 mg/m2 on days 6 to 2) plus oral busulfan (4 mg/kg/day on
days 5 to 2) as a new conditioning regimen for allogeneic
peripheral blood stem cell transplantation in 16 CML patients in
chronic phase with matched related donors. Cyclosporine was used
as a prophylactic agent for GVHD (3 mg/kg IV till 4, 10 mg/kg
oral from day 5). 15 (94%) patients had standard and one had
high risk CML. The median patient age was 32 years (range,
11–43). The median follow-up was one year (range, 119–517
days). There was no cardiac toxicity and hemorrhagic cystitis.
Grade 1–2 and grade 3 mucositis occurred in 75% and 25%
respectively and 31% developed hepatic toxicity which resolved
with conservative therapy. 37.5% experienced moderate to severe
headache. The median of highest serum creatinine level during
hospitalization were 1.5 mg/dl (range, 1–3.6; 25% with Cr2) and
serum cyclosporine level, at the same time, was 158 ng/ml (range,
9–429). Incidence of acute GVHD grade 1–2 and grade 3 were
37.5% and 19% respectively. Grade 4 acute GVHD was found in
one patient. 50% showed limited chronic GVHD. 31% of patients
became CMV (min 48, max 69). The median times for neu-
trophil and platelet recovery were 11 (min 0, max19) and 14 (min
0, max 30) days. In day 38, 87.5% of the patients had 90% or
more, mononuclear chimerism (with STR-PCR technique; me-
dian, 100%; range, 93–100). There was no molecular relapse.
Nonrelapse mortality was 25% (4 patients; acute GVHD grade
IV1, CMV infection and GVHD1, pneumonia1, infec-
tion1). With a median follow up of one year (range, 4–17
months), the probabilities of overall survival and disease free sur-
vival were both 75%. In another study in our center, using busulfan
and cyclophosphamide as standard conditioning regimen for 112
CML patients in chronic phase, the probability of overall survival,
with the same median time of follow up, was 53.57%. So it seems
that ﬂudarabine could be well tolerated in standard conditioning
regimen versus cyclophosphamide for patients with standard risk
CML in chronic phase, but it deserves further studies to establish.
65
IN VIVO T CELL DEPLETED UNRELATED ALLOGENEIC STEM CELL
TRANSPLANTATION WITH A REDUCED INTENSITY REGIMEN IN PA-
TIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
Magalhaes-Silverman, M.; Carter, T.; Gingrich, R.; Hohl, R.; Schlu-
eter, A. University of Iowa, Iowa City, IA.
Background:Graft versus host disease (GVHD) remains a major
cause of mortality after transplantation. Reduced intensity condi-
tioning (RIC) regimens followed by allogeneic stem cell transplan-
tation (SCT) with in vivo T-cell depletion using Campath-1H have
been shown to decrease the incidence of GVHD. We report our
experience with such an approach in 19 patients (pts) with ad-
vanced hematologic malignancies undergoing unrelated SCT.
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